Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,613 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Cohort A Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

NCT07090889
View directory record Official record
Conditions
Olmsted Syndrome
Interventions
KM-023, Placebo
Drug
Lead sponsor
Orvida Pharma (formerly Kamari Pharma)
Network
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee

NCT04229225
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
UBX0101, Placebo
Drug · Other
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
The Villages, Florida • Marietta, Georgia • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

NCT01200420
View directory record Official record
Conditions
Hepatitis C
Interventions
miravirsen, saline
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

NCT00740610
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
GS-9450, GS-9450 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
31
States / cities
Tucson, Arizona • Fresno, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

NCT02951182
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ, IVA, VX-440, Matched Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

NCT03802396
View directory record Official record
Conditions
Postoperative Delirium, Postoperative Cognitive Dysfunction
Interventions
CN-105, Placebo
Drug
Lead sponsor
Miles Berger, MD PhD
Other
Eligibility
60 Years and older
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04537208
View directory record Official record
Conditions
COVID-19 (Healthy Volunteers)
Interventions
CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

NCT00990613
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon IR, Dimebon Transdermal
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Research Study Investigating Mim8 in People With Haemophilia A

NCT04204408
View directory record Official record
Conditions
Healthy Volunteers, Haemophilia A With or Without Inhibitors
Interventions
NNC0365-3769 (Mim8), Placebo (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

NCT01339897
View directory record Official record
Conditions
Healthy
Interventions
5 mg/N6022, Placebo, 10mg/N6022, 20mg/N6022
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Sep 30, 2026, 1:59 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

NCT07517133
View directory record Official record
Conditions
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions
Mitapivat, Placebo Matching Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Palo Alto, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

NCT04742517
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

NCT03060538
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease
Interventions
BFKB8488A, Placebo
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Anniston, Alabama • Coronado, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Sep 30, 2026, 1:59 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

NCT05123755
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
Interventions
AV-001 Injection, AV-001 Placebo Injection
Drug
Lead sponsor
Vasomune Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Newport Beach, California • Denver, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 1:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

NCT01499017
View directory record Official record
Conditions
Healthy
Interventions
PF-06291874 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-071 in People With Parkinson Disease

NCT04334317
View directory record Official record
Conditions
Parkinson Disease, Healthy Participants
Interventions
TAK-071, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Garden Grove, California • Irvine, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants

NCT05541315
View directory record Official record
Conditions
Healthy
Interventions
JNJ-88260237, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

NCT02567773
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

NCT01409122
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Sep 30, 2026, 1:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

NCT03787095
View directory record Official record
Conditions
HIV Infections
Interventions
Cemiplimab, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 30, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

NCT06570369
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Healthy
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Garden Grove, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 30, 2026, 1:59 PM EDT